- Home
- TRDA vs PAII Comparison
TRDA vs PAII Comparison
Compare TRDA & PAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- PAII
- Stock Information
- Founded
- TRDA 2016
- PAII 2025
- Country
- TRDA United States
- PAII United States
- Employees
- TRDA N/A
- PAII N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- PAII
- Sector
- TRDA Health Care
- PAII
- Exchange
- TRDA Nasdaq
- PAII Nasdaq
- Market Cap
- TRDA 235.4M
- PAII 271.3M
- IPO Year
- TRDA 2021
- PAII 2025
- Fundamental
- Price
- TRDA $6.95
- PAII $10.06
- Analyst Decision
- TRDA Strong Buy
- PAII
- Analyst Count
- TRDA 3
- PAII 0
- Target Price
- TRDA $25.67
- PAII N/A
- AVG Volume (30 Days)
- TRDA 187.5K
- PAII 104.9K
- Earning Date
- TRDA 11-06-2025
- PAII 01-01-0001
- Dividend Yield
- TRDA N/A
- PAII N/A
- EPS Growth
- TRDA N/A
- PAII N/A
- EPS
- TRDA N/A
- PAII N/A
- Revenue
- TRDA $79,476,000.00
- PAII N/A
- Revenue This Year
- TRDA N/A
- PAII N/A
- Revenue Next Year
- TRDA N/A
- PAII N/A
- P/E Ratio
- TRDA N/A
- PAII N/A
- Revenue Growth
- TRDA N/A
- PAII N/A
- 52 Week Low
- TRDA $4.93
- PAII $9.92
- 52 Week High
- TRDA $21.79
- PAII $10.10
- Technical
- Relative Strength Index (RSI)
- TRDA 60.76
- PAII N/A
- Support Level
- TRDA $6.60
- PAII N/A
- Resistance Level
- TRDA $7.54
- PAII N/A
- Average True Range (ATR)
- TRDA 0.43
- PAII 0.00
- MACD
- TRDA 0.06
- PAII 0.00
- Stochastic Oscillator
- TRDA 70.38
- PAII 0.00
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
About PAII Pyrophyte Acquisition Corp. II Class A Ordinary Shares
Pyrophyte Acquisition Corp II is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.